Man hands holding global network and data customer connection on nature background
Featured Story

Charles River Integrates Cell and Gene Therapy Acquisitions to Enhance End-to-End Offering for Developers

The promise offered by cell and gene therapies is currently tempered by the many challenges associated with developing them. Identifying a partner that can help guide, innovate, and navigate around them is a critical success factor for any program. Committed to this form of collaboration and support for our cell and gene therapy clients, we are pleased to announce the full integration of Cognate BioServices, Cobra BiologicsVigene Biosciences, Hemacare, Cellero, Distributed Bio, Retrogenix into Charles River.

Today’s announcement marks another key milestone in our mission to invest in the tools, talent, and capacity to further the new frontier of regenerative medicine.  With the benefit of a shared quality system, faster internal technical transfer, and process crossover between teams helping to reduce program bottlenecks and providing a seamless experience, we are now uniquely positioned to help our clients accelerate and achieve critical development goals from discovery to commercialization.

We have supported the development of 10 FDA-approved cell and gene therapies and have conducted more than 900 studies in this field over the past year. A key aim of this integration is to enhance client access to this wealth of scientific and regulatory experience as well as harnesses the power of our multidisciplinary bench of experts to problem solve in a collaborative manner every step of the way.

Learn about our end-to-end cell and gene therapy portfolio of services and products.

 

Access our end-to-end CGT offering